JUUL is striving for FDA approval as data from their first study is released.
For many people, using JUUL pods has been an effective way to help with combating their addiction to traditional cigarettes. JUUL, much like many other vaping companies is looking to get the FDA golden tick of approval to make their products more readily available across markets.
JUUL’s first study data has been released. While it may not be a surprise, it’s a proactive approach to pushing vaping to the next level. This is one of the first studies undertaken by JUUL Labs. They have three others already underway. They’re hoping to stay on track to achieve FDA approval for their products by 2022.
The makers of JUUL pods have long argued that JUUL is a safer alternative to traditional cigarettes and a useful smoking cessation aid. This was proven in a study published in the New England Journal of Medicine in January. In this study vaping was shown to be almost twice as effective as nicotine gums and nicotine patches. Both of which can be extremely expensive.
What Comes Next?
The next step in their quest for FDA approval was to compare the safety of JUUL pods to traditional cigarettes. They had released a lot of data showing that there was a huge decrease in a variety of different cancer-related biomarkers when users switched from cigarettes to the JUUL.
While the news is good for vapers, it’s nothing that many vapers didn’t already know. JUUL Labs was the sponsor of the study. The research was conducted by Celerion Inc., a third-party research company.
This study was only a small sample. There are still many health and safety concerns to be addressed in vaping. However, it’s a positive step forward for vaping in general.
What The JUUL Study Tells Us!
The study utilized 90 adult smokers and looked for changes in nine specific short-term, cancer biomarkers. All the cancer-related biomarkers are a byproduct from smoking traditional cigarettes. The study participants were split into six groups of 15. One group went cold turkey, one kept smoking their normal cigarettes, and the other four groups used a different flavored JUUL pod.
There was an 85% reduction from the baseline in the nine selected biomarkers among the abstinence group and the combined JUUL groups. The cancer-related biomarkers instead rose up by almost 14% among the smokers that kept smoking.
While this is great for vapers and vaping companies, the results weren’t entirely unexpected. This initial study was only a fraction of the data needed to push the case of vaping towards regulatory approval by agencies such as the FDA, but it’s a positive step forward.
For vaping to continue moving forward, it needs to take steps to obtain regulatory approval. This could allow vaping companies to promote their products as cigarette cessation tools. Getting them into the hands of smokers around the world.